This silencing will then activate the release of C-C motif chemokine ligand 2 (CCL2) from tumor cells, allowing myeloid cell recruitment via their C-C chemokine receptor type 2 (CCR2), which in turn will promote the chemotaxis and chemokinesis of tumor cells, and therefore tumor cell invasiveness34. This evidence concerns the gene CCR2 and neoplasm.